Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...
Investor's Business Daily on MSN5d
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' ContinuesInsulet stock soared out of a buy zone Friday after the insulin pump-maker "continued the beat-and-raise cadence it has seen in 2024." ...
Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback